Rhabdomyolysis Following Initiation of Posaconazole Use for Antifungal Prophylaxis in a Patient With Relapsed Acute Myeloid Leukemia

• Type of Material: Article
• Authors: Mayur D. Mody, Emory University; Deepak Ravindranathan, Emory University; Harpaul S. Gill, Emory University; Vamsi Kota, Emory University
• Language: English
• Date: 2017-01
• Publisher: SAGE Publications (UK and US): Creative Commons Attribution
• Publication Version: Final Published Version
• Copyright Statement: © 2017 American Federation for Medical Research
• License: Creative Commons Attribution 3.0 Unported
• Final Published Version (URL): http://dx.doi.org/10.1177/2324709617690747
• Title of Journal or Parent Work: Journal of Investigative Medicine High Impact Case Reports
• ISSN: 2324-7096
• Volume: 5
• Issue: 1
• Start Page: 232470961769074
• End Page: 232470961769074
• Grant/Funding Information: The author(s) received no financial support for the research, authorship, and/or publication of this article.
• Keywords: posaconazole; rhabdomyolysis; AML; acute myeloid leukemia
• Research Categories: Health Sciences, General; Health Sciences, Oncology

Abstract

Posaconazole is a commonly used medication for antifungal prophylaxis in patients with high-risk acute leukemia, such as acute myeloid leukemia. Despite clinical data that show that posaconazole is superior to other antifungal prophylaxis medications, posaconazole is known to have many side effects and drug-drug interactions. We present a patient who developed rhabdomyolysis after being started on posaconazole for prophylaxis in the setting of relapsed acute myeloid leukemia.